盐酸缬更昔洛韦片治疗CMV视网膜炎的效果好吗？

Valcyte is indicated for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients. Valganciclovir hydrochloride tablets are sensitive to human viruses including human cytomegalovirus (HCMV), and valganciclovir hydrochloride tablets (Valcyte) are sensitive to herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV) and hepatitis B virus.

Is Valganciclovir Hydrochloride Tablets effective in treating CMV retinitis?

The antiviral effect of Valganciclovir hydrochloride tablets (Valganciclovir) has been clinically confirmed by treating AIDS patients with newly diagnosed retinitis (clinical study WV15376). After four weeks of treatment with valganciclovir hydrochloride tablets, the detection rate of CMV virus decreased from 46% (32/69) at study enrollment to 7% (4/55). Clinical studies of valganciclovir hydrochloride tablets in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week four was the same in both groups. After induction therapy, both groups of patients in this study continued to receive maintenance therapy with valganciclovir hydrochloride tablets 900 mg per day. In patients who received induction therapy with valganciclovir or intravenous ganciclovir followed by maintenance therapy with valganciclovir, the mean (median) time from randomization to progression of CMV retinitis was 226 (160) days and 219 (125) days, respectively. Oral tablets achieve similar body exposure to ganciclovir when administered at recommended doses of intravenous ganciclovir and are effective in the treatment of CMV retinitis.